person · Reporting owner

LYONS GARY A

Disclosed activity across 6 companies

Tapewire entity: 21784
SEC CIK: 0001123343

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERENOME, INC.CTYX · Entity 7637	Director	November 28, 2017	February 09, 2018
Eledon Pharmaceuticals, Inc.ELDN · Entity 6160	Director	May 01, 2023	May 02, 2023
Fresh Tracks Therapeutics, Inc.BBI · Entity 90076	Director	May 17, 2022	May 17, 2022
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655	Director	May 27, 2026	May 29, 2026
RIGEL PHARMACEUTICALS INCRIGL · Entity 2423	Director	May 26, 2023	July 12, 2023
Travere Therapeutics, Inc.TVTX · Entity 1562	Director	August 17, 2026	August 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERENOME, INC.

Report date November 28, 2017 · Filed February 09, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Subscription Rights (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2017-11-21	Direct	0	Reported balance After 2017-11-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-11-28 · Other · Disposed 1 · Balance 0 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.33	Direct	1	Reported balance After 2017-11-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-11-28 · Other · Acquired 1 · Balance 1 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2: The Series B Preferred Stock has no expiration date.
Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2020-05-28	Direct	1,800	Reported balance After 2017-11-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-28 · Other · Acquired 1,800 · Balance 1,800 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.

F2: The Series B Preferred Stock has no expiration date.

F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.

Eledon Pharmaceuticals, Inc.

Report date May 01, 2023 · Filed May 02, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-05-01	Direct	150,437	Reported balance After 2023-05-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-05-01 · Grant · Acquired 150,437 · Balance 150,437 F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.

Fresh Tracks Therapeutics, Inc.

Report date May 17, 2022 · Filed May 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2032-05-17	Direct	65,000	Reported balance After 2022-05-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-17 · Grant · Acquired 65,000 · Balance 65,000

NEUROCRINE BIOSCIENCES INC

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,284	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 1,284 · Balance 1,284 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $155.83 · Expires 2036-05-27	Direct	2,624	Reported balance After 2026-05-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-27 · Grant · Acquired 2,624 · Balance 2,624 F3: Option vests in 12 monthly installments beginning June 27, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2: The RSUs will vest in full on May 27, 2027.

F3: Option vests in 12 monthly installments beginning June 27, 2026.

RIGEL PHARMACEUTICALS INC

Report date May 26, 2023 · Filed July 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	75,000	Reported balance After 2023-05-26 transaction · row 1 1 source row Row 1 · 2023-05-26 · Grant · Acquired 25,000 · Balance 75,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2033-05-26	Direct	30,000	Reported balance After 2023-05-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-26 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Travere Therapeutics, Inc.

Report date August 17, 2026 · Filed August 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	61,500	Ending reported balance After 2026-08-18 transaction · row 7 7 source rows · reconciled sequence Row 1 · 2026-08-17 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 2 · 2026-08-17 · Sale · Disposed 1,900 · Balance 64,600 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-08-17 · Sale · Disposed 2,600 · Balance 62,000 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-08-17 · Sale · Disposed 500 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 6 · 2026-08-18 · Sale · Disposed 4,100 · Balance 62,400 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 7 · 2026-08-18 · Sale · Disposed 900 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17	Direct	5,000	Reported balance After 2026-08-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-08-17 · Exercise / conversion · Disposed 5,000 · Balance 5,000 F7: The stock option is fully vested and exercisable.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17	Direct	0	Reported balance After 2026-08-18 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-08-18 · Exercise / conversion · Disposed 5,000 · Balance 0 F7: The stock option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F7: The stock option is fully vested and exercisable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionStock option (right to buy) · Derivative	5,000	$0.00 Strike: $17.44	$0.00	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · derivative · entry 9 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
August 18, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	900	$63.86	$57,470.13	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 7 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,500 F1 · kind: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F6 · price: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
August 18, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	4,100	$63.27	$259,390.19	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 6 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,400 F1 · kind: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F5 · price: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
August 18, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionCommon Stock	5,000	$17.44	$87,200.00	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 5 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionStock option (right to buy) · Derivative	5,000	$0.00 Strike: $17.44	$0.00	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · derivative · entry 8 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	500	$64.16	$32,081.00	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 4 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,500 F1 · kind: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F4 · price: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	2,600	$63.50	$165,099.74	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 F1 · kind: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F3 · price: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	1,900	$62.53	$118,804.91	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,600 F1 · kind: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F2 · price: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionCommon Stock	5,000	$17.44	$87,200.00	Disclosure SEC source: 0001123343-26-000010 · form4-08192026_040801.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 27, 2026 Filed May 29, 2026 22:04 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	2,624	$0.00 Strike: $155.83	$0.00	Disclosure SEC source: 0001123343-26-000008 · wk-form4_1780092285.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,624 Underlying: Common Stock · 2,624 shares Expires 2036-05-27 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 27, 2026. Read SEC document
May 27, 2026 Filed May 29, 2026 22:04 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestriced Stock Unit · Derivative	1,284	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001123343-26-000008 · wk-form4_1780092285.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,284 Underlying: Common Stock · 1,284 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document
May 21, 2026 Filed May 21, 2026 23:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001123343-26-000006 · wk-form4_1779405659.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document
May 21, 2026 Filed May 21, 2026 23:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,659	$0.00	$0.00	Disclosure SEC source: 0001123343-26-000006 · wk-form4_1779405659.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power Read SEC document
May 19, 2026 Filed May 21, 2026 21:00 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantStock option (right to buy) · Derivative	12,000	$0.00 Strike: $42.26	$0.00	Disclosure SEC source: 0001123343-26-000004 · form4-05212026_050508.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document
May 19, 2026 Filed May 21, 2026 21:00 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001123343-26-000004 · form4-05212026_050508.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document
April 14, 2026 Filed Apr 16, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionStock option (right to buy) · Derivative	8,000	$0.00 Strike: $16.33	$0.00	Disclosure SEC source: 0001123343-26-000002 · form4-04162026_040407.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
April 14, 2026 Filed Apr 16, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	8,000	$41.07	$328,560.00	Disclosure SEC source: 0001123343-26-000002 · form4-04162026_040407.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 11, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 18, 2026. Read SEC document
April 14, 2026 Filed Apr 16, 2026 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionCommon Stock	8,000	$16.33	$130,640.00	Disclosure SEC source: 0001123343-26-000002 · form4-04162026_040407.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 03, 2025 Filed Dec 4, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	15,000	$0.00 Strike: $47.89	$0.00	Disclosure SEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026. Read SEC document
December 03, 2025 Filed Dec 4, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	15,000	$152.61	$2,289,082.50	Disclosure SEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,482 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.63 to $154.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: 114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
December 03, 2025 Filed Dec 4, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	15,000	$47.89	$718,350.00	Disclosure SEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 22, 2025 Filed May 22, 2025 21:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000127 · wk-form4_1747948689.xml · derivative · entry 4 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F5 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. F5 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. Read SEC document
May 22, 2025 Filed May 22, 2025 21:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,435	$0.00	$0.00	Disclosure SEC source: 0000914475-25-000127 · wk-form4_1747948689.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power Read SEC document
May 21, 2025 Filed May 22, 2025 21:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	3,305	$0.00 Strike: $120.56	$0.00	Disclosure SEC source: 0000914475-25-000127 · wk-form4_1747948689.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,305 Underlying: Common Stock · 3,305 shares Expires 2035-05-21 F4 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 21, 2025. Read SEC document
May 21, 2025 Filed May 22, 2025 21:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000127 · wk-form4_1747948689.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,659 Underlying: Common Stock · 1,659 shares Expires not disclosed F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026. F3 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026. Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantStock option (right to buy) · Derivative	19,500	$0.00 Strike: $21.15	$0.00	Disclosure SEC source: 0001415889-25-013499 · form4-05162025_070509.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-05-15 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantCommon Stock	6,500	$0.00	$0.00	Disclosure SEC source: 0001415889-25-013499 · form4-05162025_070509.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document
October 04, 2024 Filed Oct 4, 2024 23:15 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionStock option (right to buy) · Derivative	40,000	$0.00 Strike: $10.48	$0.00	Disclosure SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · derivative · entry 4 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2024-10-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
October 04, 2024 Filed Oct 4, 2024 23:15 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	18,821	$15.15	$285,226.61	Disclosure SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,000 F1 · kind: This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024. F3 · price: The weighted average sale price for the transaction reported was $15.1547, and the range of prices were between $14.92 and $15.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
October 04, 2024 Filed Oct 4, 2024 23:15 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	SaleCommon Stock	21,179	$14.35	$303,874.17	Disclosure SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,821 F1 · kind: This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024. F2 · price: The weighted average sale price for the transaction reported was $14.3479, and the range of prices were between $13.92 and $14.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document
October 04, 2024 Filed Oct 4, 2024 23:15 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	Exercise / conversionCommon Stock	40,000	$10.48	$419,200.00	Disclosure SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	11,570	$0.00 Strike: $42.76	$0.00	Disclosure SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,570 shares Expires 2025-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	11,570	$150.43	$1,740,449.65	Disclosure SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,047 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024 F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range F1 · ownership.direct: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	11,570	$42.76	$494,733.20	Disclosure SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	930	$0.00 Strike: $42.76	$0.00	Disclosure SEC source: 0000914475-24-000172 · wk-form4_1721336035.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,570 Underlying: Common Stock · 930 shares Expires 2025-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	930	$150.03	$139,530.23	Disclosure SEC source: 0000914475-24-000172 · wk-form4_1721336035.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,047 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024 F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F1 · balance_after: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	930	$42.76	$39,766.80	Disclosure SEC source: 0000914475-24-000172 · wk-form4_1721336035.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
May 22, 2024 Filed May 23, 2024 22:17 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	2,982	$0.00 Strike: $139.43	$0.00	Disclosure SEC source: 0000914475-24-000146 · wk-form4_1716502667.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,982 Underlying: Common Stock · 2,982 shares Expires 2034-05-22 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 22, 2024. Read SEC document
May 22, 2024 Filed May 23, 2024 22:17 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-24-000146 · wk-form4_1716502667.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435 Underlying: Common Stock · 1,435 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025. Read SEC document
May 17, 2024 Filed May 21, 2024 20:57 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000129 · wk-form4_1716325029.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. Read SEC document
May 17, 2024 Filed May 21, 2024 20:57 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000129 · wk-form4_1716325029.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
May 14, 2024 Filed May 16, 2024 20:55 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	12,500	$42.76 Strike: $42.76	$534,500.00	Disclosure SEC source: 0000914475-24-000123 · wk-form4_1715892908.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2025-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. Read SEC document
May 14, 2024 Filed May 16, 2024 20:55 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	12,500	$135.63	$1,695,370.00	Disclosure SEC source: 0000914475-24-000123 · wk-form4_1715892908.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,947 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $134.78 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · ownership.direct: 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
May 14, 2024 Filed May 16, 2024 20:55 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	12,500	$42.76	$534,500.00	Disclosure SEC source: 0000914475-24-000123 · wk-form4_1715892908.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reflects a decrease of 76,750 shares from the amount previously reported as beneficially owned, which was recently discovered to be overstated due to an administrative oversight. F2 · ownership.direct: 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
May 08, 2024 Filed May 10, 2024 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantStock option (right to buy) · Derivative	19,500	$0.00 Strike: $6.82	$0.00	Disclosure SEC source: 0001415889-24-012847 · form4-05102024_040530.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2034-05-07 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document
May 08, 2024 Filed May 10, 2024 20:05 UTC	Travere Therapeutics, Inc. TVTX · Entity 1562	GrantCommon Stock	6,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-012847 · form4-05102024_040530.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:10 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	10,000	$130.04	$1,300,443.00	Disclosure SEC source: 0001209191-23-059771 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	5,000	$12.98 Strike: $12.98	$64,900.00	Disclosure SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	5,000	$116.77	$583,837.00	Disclosure SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:54 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	5,000	$12.98	$64,900.00	Disclosure SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.